R Squared Ltd Has $3.03 Million Holdings in Boston Scientific Corporation $BSX

R Squared Ltd boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 102.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,033 shares of the medical equipment provider’s stock after acquiring an additional 15,677 shares during the period. Boston Scientific accounts for 1.3% of R Squared Ltd’s investment portfolio, making the stock its 2nd largest holding. R Squared Ltd’s holdings in Boston Scientific were worth $3,030,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BSX. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp boosted its position in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Geode Capital Management LLC grew its holdings in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank acquired a new stake in Boston Scientific during the 2nd quarter worth about $2,089,937,000. Finally, Invesco Ltd. raised its position in shares of Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after acquiring an additional 226,578 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $75.77 on Friday. Boston Scientific Corporation has a 12-month low of $72.69 and a 12-month high of $109.50. The business’s fifty day moving average is $87.69 and its 200 day moving average is $95.83. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock has a market cap of $112.43 billion, a P/E ratio of 39.06, a P/E/G ratio of 1.02 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the business posted $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. Citigroup cut their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. TD Cowen cut their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. The Goldman Sachs Group set a $99.00 price objective on shares of Boston Scientific in a research note on Thursday, February 5th. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, National Bank Financial set a $115.00 price target on shares of Boston Scientific in a report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.